Insights

AI-Driven Vaccines Evaxion leverages its AI-Immunology platform to develop personalized cancer vaccines and infectious disease therapies, indicating potential sales opportunities for AI-driven analytics, biomarker discovery, and companion diagnostics services that support precision immunotherapy programs.

Clinical-Stage Pipeline With a clinical-stage oncology vaccine portfolio and ongoing expansion of programs such as EVX-05 for glioblastoma, there is a pathway for collaborations, co-development rights, or licensing deals for advanced immunotherapies and associated manufacturing or data services.

Autoimmune and Tolerogenic Programs Recent news indicates a focus on autoimmune disease treatments and tolerogenic vaccine concepts, suggesting cross-application opportunities in partnering for bespoke vaccine design, immunomodulatory research services, and early-access programs for autoimmune indications.

Financing and Valuation Signals Recent financing activity and a mid-level market valuation imply a receptive environment for strategic partnerships, equity-backed collaborations, or toll-gate funding discussions to accelerate pipeline advancement and scale consulting or development services.

Technical and Collaborations Edge Evaxion’s tech stack (Kubernetes, Terraform, PostgreSQL, cloud platforms) and collaboration with Duke University for EVX-04/EVX-05 highlight potential for data infrastructure services, cloud-based computing partnerships, and joint computational biology or bioinformatics service packages.

Evaxion A/S Tech Stack

Evaxion A/S uses 8 technology products and services including Grafana, Ansible, HashiCorp Terraform, and more. Explore Evaxion A/S's tech stack below.

Grafana

Analytics

Ansible

Configuration Management

HashiCorp Terraform

Configuration Management

Kubernetes

Containerization

PostgreSQL

Database

Dropbox

Digital Asset Management

Microsoft 365

Microsoft Azure

Platform As A Service

Evaxion A/S Email Formats	Example	Percentage
Last@evaxion-biotech.com	Doe@evaxion-biotech.com	65%
FL@evaxion-biotech.com	JD@evaxion-biotech.com	35%
FL@evaxion.ai	JD@evaxion.ai	100%

Evaxion A/S Email Formats

Example

Percentage

Last@evaxion-biotech.com

Doe@evaxion-biotech.com

65%

FL@evaxion-biotech.com

JD@evaxion-biotech.com

35%

FL@evaxion.ai

JD@evaxion.ai

100%

Frequently Asked Questions

What is Evaxion A/S's official website and social media links?

Evaxion A/S's official website is evaxion.ai and has social profiles on LinkedIn and Crunchbase.

How much revenue does Evaxion A/S generate?

As of November 2026, Evaxion A/S's annual revenue is estimated to be $1M - $10M.

What is Evaxion A/S's SIC code and NAICS code?

Evaxion A/S's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Evaxion A/S have currently?

As of November 2026, Evaxion A/S has approximately 51 employees across 2 continents, including Europe and North America. Key team members include Chief Executive Officer: H. T., Chief Financial Officer: T. F. S. and Chief Ai Officer, Founder: A. H. M. Explore Evaxion A/S's employee directory with LeadIQ.

What industry does Evaxion A/S belong to?

Evaxion A/S operates in the Biotechnology Research industry.

What technology does Evaxion A/S use?

Evaxion A/S's tech stack includes Grafana, Ansible, HashiCorp Terraform, Kubernetes, PostgreSQL, Dropbox, Microsoft 365 and Microsoft Azure.

What is Evaxion A/S's email format?

Evaxion A/S's email format typically follows the pattern of Last@evaxion-biotech.com. Find more Evaxion A/S email formats with LeadIQ.

How much funding has Evaxion A/S raised to date?

As of November 2026, Evaxion A/S has raised $114M in funding. The last funding round occurred on Oct 30, 2025 for $4.1M.

When was Evaxion A/S founded?

Evaxion A/S was founded in 2008.

Evaxion A/S

Q: What is Evaxion A/S's official website and social media links?

Evaxion A/S's official website is evaxion.ai. Evaxion A/S has social profiles on LinkedIn.

Q: How many employees does Evaxion A/S have currently?

Evaxion A/S has approximately 51 employees.

Q: What technology does Evaxion A/S use?

Evaxion A/S's tech stack includes JSZip, Azure Active Directory, X-XSS-Protection, libvirt, macOS.

Q: What is Evaxion A/S's NAICS code?

Evaxion A/S's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchHovedstaden, Denmark51-200 Employees

Evaxion A/S is a biotechnology research company based in Hørsholm, Denmark, focused on applying artificial intelligence to immunology. Its AI-Immunology platform is used to decode the human immune system in order to develop novel immunotherapies and vaccines for cancer, bacterial infections, and viral diseases, including personalized cancer vaccines and preclinical infectious disease programs. The company operates in a clinical-stage and preclinical space, targeting unmet medical needs by offering approaches that aim to design targeted treatments and vaccines. Its activities position it within the TechBio segment, combining computational methods with a focus on immune-related therapies. In addition to its core pipelines, Evaxion has engaged in collaborations and activities such as presenting AI-based vaccine design concepts and pursuing partnerships, including with the Gates Foundation, as part of its ongoing research and development efforts.

Insights

Similar companies to Evaxion A/S

Idorsia Pharmaceuticals Ltd

IO Biotech

GO Therapeutics

Immunovia AB

Evaxion A/S Tech Stack

Media & News

Evaxion receives the Prix Galien Award for Best Medical Technology/AI Advances in the Nordic and high-growth European and Middle Eastern countries in Dec '25, recognizing its medical innovation and AI technology.

Evaxion receives the 2026 International Prix Galien Award for AI-Immunology(TM) as best digital health solution, with CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson receiving the award in New York on Oct 29th '26.

Evaxion is developing EVX-04, an experimental vaccine for acute myeloid leukemia, a type of blood cancer.

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting in Arizona in Nov '26.

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Arizona from Nov 4th-8th '26.

Evaxion is applying its AI-Immunology(TM) platform to develop treatments for autoimmune diseases, testing a tolerogenic vaccine and an autoantibody binder to address significant unmet medical needs, with initial data presented in Portugal on Nov 18th '26.

Evaxion is testing an autoantibody binder concept for autoimmune diseases through its AI-Immunology platform, with data from ongoing experiments slated for presentation in Portugal on Nov 18th '26.

Evaxion A/S's Email Address Formats